Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Reveragen BioPharma, Inc.

http://www.reveragen.com/

Latest From Reveragen BioPharma, Inc.

Santhera Raises CHF45m Ahead Of Duchenne Drug Filing

A mix of equity and debt financing has raised enough to satisfy Santhera's liquidity needs until mid-2022, which will be after the Swiss firm has filed its Duchenne drug vamorolone.

Business Strategies Financing

Santhera Eyes US Market Potential After DMD Candidate Tests Positive

Just under a year since Santhera restructured after disappointing late-stage clinical results with another DMD candidate, the Switzerland-headquartered company has reported positive top-line results in the condition with licensed-in vamorolone, and is planning for commercialization in late 2022/early 2023.

Clinical Trials Rare Diseases

Santhera Restructuring: Discontinues Lead DMD Candidate

Switzerland’s Santhera is to restructure its business and seek extra funding after the failure of Puldysa (idebenone) in a Phase III Duchenne muscular dystrophy study at interim analysis.

Clinical Trials Rare Diseases

Santhera Doubles Its DMD Portfolio By Taking Option On Vamorolone

Deal Snapshot: Santhera acquires all rights to vamorolone from Idorsia, making it ReveraGen’s direct partner on the novel Duchenne muscular dystrophy therapy.

Deals Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
      • ADMET
UsernamePublicRestriction

Register